“…Case-control studies may mask clinically relevant characteristics of subgroups of individuals with SMI. Recent studies using a comprehensive selection of inflammatory and immune-related markers in SMI have revealed considerable variation in the degree of dysregulation (Bishop et al, 2022; Boerrigter et al, 2017; Enrico et al, 2023; Fillman et al, 2016, 2014; Hoang et al, 2022; Lizano et al, 2023a, 2020; Sæther et al, 2023; Tamminga et al, 2021; Zhang et al, 2022). A consistent finding is that 30-50% of individuals with SMI show inflammatory-immune dysregulation (Bishop et al, 2022; Boerrigter et al, 2017; Lizano et al, 2023a, 2020; Zhang et al, 2022), which is associated with several unfavorable outcomes, including cognitive impairment (Fillman et al, 2016; Lizano et al, 2023a, 2020).…”